排序方式: 共有24条查询结果,搜索用时 15 毫秒
11.
Fabrizio Vernieri Nicoletta Brunelli Marilena Marcosano Cinzia Aurilia Gabriella Egeo Carlo Lovati Valentina Favoni Armando Perrotta Ilaria Maestrini Renata Rao Luigi d'Onofrio Cinzia Finocchi Marco Aguggia Francesco Bono Angelo Ranieri Maria Albanese Vittorio Di Piero Sabina Cevoli Claudia Altamura Piero Barbanti for the GARLIT Study Group 《European journal of neurology》2023,30(1):224-234
12.
Calvin Chan 《Expert opinion on biological therapy》2020,20(8):947-953
ABSTRACT
Introduction
The involvement of the calcitonin gene-related peptide (CGRP) pathway in primary headache disorders, especially migraine, had led to recent success in the development of new migraine therapies. The CGRP pathway also plays a role in the pathophysiology of cluster headache, so CGRP pathway monoclonal antibodies have been studied in the prevention of cluster headache attacks. 相似文献13.
14.
15.
16.
17.
Francesca Schiano di Cola Marco Bolchini Giulia Ceccardi Salvatore Caratozzolo Paolo Liberini Renata Rao Alessandro Padovani 《European journal of neurology》2023,30(6):1764-1773
Background and purpose
Based on their pharmacological target, two classes of calcitonin-gene-related peptide (CGRP) monoclonal antibodies (mAbs) have been identified: antibodies against the CGRP ligand—galcanezumab, fremanezumab, eptinezumab—and antibodies against the CGRP receptor (CGRP-R), erenumab. The aim of the present study was to compare anti-CGRP versus anti-CGRP-R mAbs in patients with high frequency episodic and chronic migraine.Methods
All patients on monthly treatment with anti-CGRP mAbs with an available 6 months’ follow-up at January 2022 were included. Data on efficacy outcome were collected following one (T1), three (T3) and six (T6) months of treatment, and included monthly headache/migraine days, the Migraine Disability Assessment Scale (MIDAS) and Headache Impact Test 6 (HIT-6) scores, pain intensity, analgesics consumption and response rates (>50% headache days reduction compared to baseline).Results
In all, 152 patients were enrolled, of whom 68 were in treatment with anti-CGRP mAbs (49 galcanezumab, 19 fremanezumab) and 84 with the anti-CGRP-R (erenumab). MIDAS scores were significantly lower in the anti-CGRP group at T1 and T3 (respectively p < 0.02 and p < 0.03) as well as the number of mean migraine days at T3 (p < 0.01). At T3 and T6 outcome measures were comparable, although a significantly higher percentage of super-responders was found in the anti-CGRP group (respectively p < 0.04 and p < 0.05), with a similar overall percentage of responders.Conclusions
The present study on a real-world sample confirms the beneficial effect of both anti-CGRP and anti-CGRP-R mAbs, with a more favorable outcome for anti-CGRP antibodies. 相似文献18.
19.
20.